Chemistry Research Laboratory, University of Oxford, Mansfield Road, OX1 3TA, UK.
British Heart Foundation Experimental MR Unit (BMRU), University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK and Centre for Preclinical Imaging, University of Liverpool, Nuffield Wing, Sherrington Building, Crown Street, Liverpool, L69 3BX, UK.
Dalton Trans. 2020 Mar 3;49(9):2989-2993. doi: 10.1039/c9dt03761f.
The kinetically stable heptadentate gadolinium complex Gd.pDO3A (1.Gd) demonstrates significant 31P nuclear magnetic resonance (NMR) relaxation enhancement of biologically relevant phosphate species; adenosine triphosphate (ATP), phosphocreatine (PCr) and inorganic phosphate. Gd.pDO3A (1.Gd) binds these species in fast exchange, enabling the relaxation of the bulk phosphate species in solution. This gives rise to 31P relaxation enhancements up to 250-fold higher than those observed for 31P relaxation enhancements with the commercial MRI contrast agent Gd.DOTA (DOTAREM), 2. Gd.pDO3A-like complexes may have potential applications as 31P magnetic resonance contrast agents, since shortening the T1 relaxation time of phosphate species would reduce the time needed to acquire 31P-MR spectra.
动力学稳定的七齿螯合钆配合物 Gd.pDO3A(1.Gd)对生物相关磷酸盐物种(如三磷酸腺苷 (ATP)、磷酸肌酸 (PCr) 和无机磷酸盐)具有显著的 31P 核磁共振(NMR)弛豫增强作用。Gd.pDO3A(1.Gd)与这些物质快速结合,从而使溶液中大量磷酸盐物质的弛豫成为可能。这导致 31P 弛豫增强高达 250 倍,比商用 MRI 造影剂 Gd.DOTA(DOTAREM)观察到的 31P 弛豫增强高 250 倍。Gd.pDO3A 类似物可能具有作为 31P 磁共振造影剂的潜在应用,因为缩短磷酸盐物质的 T1 弛豫时间将减少获得 31P-MR 谱所需的时间。